$11.70
Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Overview
52-week range
$4.47
$18
52% of range
Avg surprise (last 2)
-1.9%
Avg reaction (last 1)
-21.7%
0% positive
Latest IV / EM
98%
EM ±22.4% · $13 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-0.37 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.41 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.90 | $-0.86 | -4.7% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $-1.15 | $-1.16 | +0.9% | — | -21.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.32 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.56 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.42 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.76 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.84 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | BMO | -$0.15 | -$0.90 | +83.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $58M | — | $50M | $40M | $29M | — | $16M | $7M |
| Cost of revenue | $12M | — | $6M | $5M | $4M | — | $2M | $1M |
| Gross profit | $46M | — | $43M | $34M | $25M | — | $14M | $6M |
| Operating income | $-15M | — | $-15M | $-60M | $-79M | — | $-71M | $-77M |
| Net income | $-30M | — | $-30M | $-76M | $-94M | — | $-86M | $-91M |
| EPS (diluted) | $-0.37 | — | $-0.41 | $-1.05 | $-1.31 | — | $-1.32 | $-1.56 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $181M | $130M | $135M | $150M | $212M | $297M | $335M | $276M |
| Inventory | $7M | $6M | $4M | $3M | $3M | $3M | $3M | $2M |
| Total current assets | $277M | $229M | $208M | $219M | $265M | $360M | $374M | $305M |
| Total assets | $305M | $259M | $240M | $250M | $294M | $378M | $387M | $319M |
| Long-term debt | $164M | $209M | $207M | $205M | $203M | $201M | $176M | $174M |
| Total liabilities | $642M | $697M | $663M | $656M | $633M | $632M | $574M | $553M |
| Total equity | $-337M | $-438M | $-423M | $-406M | $-338M | $-254M | $-187M | $-234M |